Eli Lilly and Company (LLY) Position Held by Marshall & Sullivan Inc. WA
Marshall & Sullivan Inc. WA continued to hold its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,000 shares of the company’s stock at the end of the first quarter. Marshall & Sullivan Inc. WA’s holdings in Eli Lilly and were worth $644,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of the company. Atria Investments LLC boosted its stake in shares of Eli Lilly and by 9.5% in the first quarter. Atria Investments LLC now owns 39,979 shares of the company’s stock worth $3,363,000 after buying an additional 3,483 shares during the period. Parametrica Management Ltd bought a new stake in shares of Eli Lilly and during the first quarter worth about $242,000. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the period. Prospera Financial Services Inc boosted its stake in shares of Eli Lilly and by 6.7% in the first quarter. Prospera Financial Services Inc now owns 14,258 shares of the company’s stock worth $1,208,000 after buying an additional 895 shares during the period. Finally, Alpha Windward LLC boosted its stake in shares of Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the period. 75.61% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company (LLY) traded down 0.47% during trading on Friday, reaching $81.15. The company had a trading volume of 2,446,392 shares. The company has a market capitalization of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34. The firm’s 50 day moving average is $82.91 and its 200 day moving average is $81.72. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the business posted $0.86 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
A number of analysts recently issued reports on the company. Cowen and Company increased their price objective on Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a report on Monday, April 17th. Morgan Stanley cut Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective on the stock. in a report on Monday, April 17th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Monday, April 17th. BMO Capital Markets cut Eli Lilly and from a “market perform” rating to an “underperform” rating and lowered their price target for the company from $73.00 to $71.00 in a report on Monday, April 17th. Finally, Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the sale, the insider now owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 669,733 shares of company stock worth $55,845,287. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.